Goserelin, an LH-RH Agonist, in the Treatment of Women With Fibrocystic Mastopathy. a Pilot Study

References

• Andrews W. C. Hormonal management of fibrocystic disease of the breast. Journal of Reproductive Medicine 1990; 35: 87–90, supplement 1
   PubMed Web of Science ®Google Scholar
• Baker H. W., Snedecor P. A. Clinical trial of danazol for benign breast disease. American Surgeon 1979; 45: 727–729
   PubMed Web of Science ®Google Scholar
• Blichert-Toft M., Anderson A. N., Henriksen O. B., Mygind T. Treatment of mastalgia with bromocriptine: A double blind cross-over study. British Medical Journal 1979; i: 237
   Google Scholar
• Cupceancu B. Short-term tamoxifen treatment in benign breast diseases. Endocrinologie 1985a; 23: 169–177
   PubMedGoogle Scholar
• Cupceancu B. Combined tamoxifen-lynestrenol treatment in benign breast disease. Endocrinologie 1985b; 23: 265–272
   PubMedGoogle Scholar
• De Vogelaer J. P., Nagant de Deuxchaisnes C, Clerckx F., Donnez J. Effect of Goserelin implants, an LH-RH analogue, on lumbar and hip BMD as studied by the DEXA technique. Gynaecological Endocrinology 1990; 4, supplement 2, Abstract no 207
   Google Scholar
• Dhont M., Delbeke L., Van Eyck J., Voorhoof L. Danazol treatment of chronic cystic mastopathy: a clinical and hormonal evaluation. Postgraduate Medical Journal 1979; 55: 66–70, supplement 5
   PubMed Web of Science ®Google Scholar
• Doeberl A., Tobtassen T., Rasmussen T. Treatment of recurrent cyclical mastodynia in patients with fibrocystic breast disease. A double-blind placebo-controlled study-the Hjorring project. Acta Obstetricia et Gynaecologica Scandinavica 1984; 123: 177–184, supplement
   Google Scholar
• Fentiman I. S. Tamoxifen: use in benign conditions. British Journal of Clinical Practice 1988; 42: 384–387
   PubMedGoogle Scholar
• Furr B. J. A. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue Zoladex. Hormone Research 1989; 32: 86–92, supplement 1
   PubMedGoogle Scholar
• Gorins A., Perret F., Tournant B., Rogier C., Lipszyc J. A French double-blind cross-over study (danazol versus placebo) in the treatment of severe fibrocystic breast disease. European Journal of Gynaecological Oncology 1984; 5: 85–89
   PubMedGoogle Scholar
• Greenblatt B., Ben-Nun I. Danazol in the treatment of mammary dysplasia. Drugs 1980; 19: 349–355
   PubMed Web of Science ®Google Scholar
• Humphrey L. J., Estes N. C. Aspects of fibrocystic disease of the breast. Treatment with danazol. Postgraduate Medical Journal 1979; 55: 48–51, supplement 5
   PubMed Web of Science ®Google Scholar
• Lamarque J. L. Atlas of the Breast-Clinical Radiodiagnosis, G. Bang. Wolfe Medical Publications, London 1984
   Google Scholar
• Mansel R. E., Preece P. E., Hughes L. E. Treatment of cyclical breast pain with bromocriptine. Scottish Medical Journal 1980; S65–S70, Supplement
   Google Scholar
• Martin-Comin J., Pusol-Amat P. K., Cararach V., Davi E., Robyn C. Treatment of fibrocystic disease of the breast with a prolactin inhibitor 2-bromo-alpha-ergocryptine (CB 154). Obstetrics and Gynecology 1976; 48: 703–706
   PubMed Web of Science ®Google Scholar
• Mussa A., Dogliotti L. Treatment of benign breast disease with bromocriptine. Journal of Endocrinological Investigation 1979; 2: 87–91
   PubMed Web of Science ®Google Scholar
• Newling D. W. W., Denis L., Mahler C., Debruyne F. M. J., Lunglmayr G., Robinson M. R. G., Richards B. Clinical and endocrinological results with a biodegradeable depot LHRH analogue (Zoladex) in the management of advanced prostatic cancer. Zoladex-a New Treatment for Prostalic Cancer, G. D. Chisholm. International Congress and Symposium Series, Royal Society of Medicine, London 1987 17–26, number 125
   Google Scholar
• Nezhat C., Asch R. H., Greenblatt R. B. Danazol for benign breast disease. American Journal of Obstetrics and Gynecology 1980; 137: 604–607
   PubMed Web of Science ®Google Scholar
• Nicholsom R. I., Walker K. J., Turkes A., Dyas J., Plowman P. N., Williams M., Blarney R. M. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. Journal of Steroid Biochemistry 1985; 23: 843–847
   PubMedGoogle Scholar
• Pavelka R., Schneider W. H. Klinische Erfahrungen mit Danazoltherapie bei Endometriose und Mastopathie. Wiener klinische Wochenschrift 1981; 93: 595–599
   PubMedGoogle Scholar
• Poules T. J., Ford H. T., Gazet J. C. A randomized clinical trial to compare Tamoxifen with Danazol for treatment of benign mammary dysplasia. Breast-Diseases Senologia 1987; 2: 1–5
   Google Scholar
• Santoro C., Cappa M., Moretti C., Fabbri A., La Vecchia V., Romano Marcellino L., Fraioli F. Treatment of benign fibrocystic disease of the breast with 2-bromo-alpha-ergocryptine (CB154). International Journal of Clinical Pharmacology, Therapy and Toxicology 1982; 20: 479–481
   PubMedGoogle Scholar
• Shaaban M. M., Morad F., Hassan A., Hassan R. Treatment of fibrocystic mastopathy by an antiestrogen, tamoxifen. International Journal of Gynaecology and Obstetrics 1980; 18: 348–350
   PubMedGoogle Scholar
• Wentz A. C. Adverse effects of danazol in pregnancy. Annals of Internal Medicine 1982; 96: 672–673
   PubMed Web of Science ®Google Scholar